RVU — Ryvu Therapeutics SA Share Price
Last trade - 00:00- PLN1.26bn
- PLN1.04bn
- PLN46.86m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 4.86 | ||
| Price to Tang. Book | 4.98 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 26.94 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -30.27% | ||
| Return on Equity | -30.55% | ||
| Operating Margin | -215.42% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | PLNm | 3.8 | 15.65 | 11.19 | 38.95 | 46.86 | 182.65 | 269.7 | -9.5% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Ryvu Therapeutics SA, formerly known as Selvita SA, is a Poland-based company engaged in the healthcare industry. The Company is active in the pharmaceutical and biotechnology fields. It operates through two business segments. The Innovative segment develops new drugs mainly for oncology and central nervous system diseases. The Services segment is engaged in the research and development activities, such as introducing substances on the market, client service and reducing the risk. The Company’s portfolio encompasses projects, including kinesis inhibitors platform, the platform of the metabolism for the cancer and epigenetic, among others. Ryvu Therapeutics SA is active in the domestic market and internationally, such as in the United States. It operates through unit Ardigen SA and SORS Holdings Ltd.
Directors
- Pawel Przewiezlikowski CMG (46)
- Krzysztof Brzozka VMG
- Boguslaw Sieczkowski VMG
- Kamil Sitarz COO
- Milosz Gruca MGB
- Edyta Jaworska MGB
- Miroslawa Zydron MGB
- Rafal Chwast IND
- Axel Glasmacher SUB
- Colin Goddard SUB
- Jarl Jungnelius SUB
- Wojciech Sobieraj SUB
- Thomas Turalski SUB
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- October 6th, 2010
- Public Since
- July 14th, 2011
- No. of Employees
- 230
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Warsaw Stock Exchange
- Shares in Issue
- 23,120,140
- Address
- Leona Henryka Sternbacha 2, KRAKOW, 30-394
- Web
- https://ryvu.com/
- Phone
- +48 123140200
- Auditors
- PWC
Upcoming Events for RVU
Similar to RVU
Airway Medix SA
Warsaw Stock Exchange
Bioton SA
Warsaw Stock Exchange
Braster SA
Warsaw Stock Exchange
Captor Therapeutics SA
Warsaw Stock Exchange
E-Shopping SA
Warsaw Stock Exchange
FAQ
As of Today at 19:18 UTC, shares in Ryvu Therapeutics SA are trading at PLN54.60. This share price information is delayed by 15 minutes.
Shares in Ryvu Therapeutics SA last closed at PLN54.60 and the price had moved by -6.51% over the past 365 days. In terms of relative price strength the Ryvu Therapeutics SA share price has underperformed the FTSE Global All Cap Index by -13.76% over the past year.
The overall consensus recommendation for Ryvu Therapeutics SA is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Ryvu Therapeutics SA does not currently pay a dividend.
Ryvu Therapeutics SA does not currently pay a dividend.
Ryvu Therapeutics SA does not currently pay a dividend.
To buy shares in Ryvu Therapeutics SA you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of PLN54.60, shares in Ryvu Therapeutics SA had a market capitalisation of PLN1.26bn.
Here are the trading details for Ryvu Therapeutics SA:
- Country of listing: Poland
- Exchange: WSE
- Ticker Symbol: RVU
Based on an overall assessment of its quality, value and momentum Ryvu Therapeutics SA is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Ryvu Therapeutics SA is PLN71.17. That is 30.35% above the last closing price of PLN54.60.
Analysts covering Ryvu Therapeutics SA currently have a consensus Earnings Per Share (EPS) forecast of -PLN3.88 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Ryvu Therapeutics SA. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -25.19%.
As of the last closing price of PLN54.60, shares in Ryvu Therapeutics SA were trading -8.15% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Ryvu Therapeutics SA PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at PLN54.60.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Ryvu Therapeutics SA's management team is headed by:
- Pawel Przewiezlikowski - CMG
- Krzysztof Brzozka - VMG
- Boguslaw Sieczkowski - VMG
- Kamil Sitarz - COO
- Milosz Gruca - MGB
- Edyta Jaworska - MGB
- Miroslawa Zydron - MGB
- Rafal Chwast - IND
- Axel Glasmacher - SUB
- Colin Goddard - SUB
- Jarl Jungnelius - SUB
- Wojciech Sobieraj - SUB
- Thomas Turalski - SUB